利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.04 秒)

    DRUG SELECTION FOR LUNG CANCER THERAPY USING ANTIBODY-BASED ARRAYS
    5.
    发明申请
    DRUG SELECTION FOR LUNG CANCER THERAPY USING ANTIBODY-BASED ARRAYS 有权
    使用基于抗体的阵列进行肺癌治疗的药物选择

    公开(公告)号：US20110275097A9

    公开(公告)日：2011-11-10

    申请号：US12172100

    申请日：2008-07-11

    申请人： Sharat Singh ,  Jeanne Harvey

    发明人： Sharat Singh ,  Jeanne Harvey

    IPC分类号： G01N33/574 ,  C12M1/34

    CPC分类号： G01N33/57423 ,  G01N33/5041 ,  G01N33/5044 ,  G01N33/5082 ,  G01N2500/10 ,  G01N2800/52

    摘要： The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.

    摘要翻译： 本发明提供用于检测肿瘤细胞中信号转导途径的组分的激活状态的组合物和方法。 关于使用本发明的信号转导途径的组分的激活状态的信息可用于癌症诊断，预后和癌症治疗的设计。

    METHODS OF PREDICTING AND MONITORING TYROSINE KINASE INHIBITOR THERAPY
    6.
    发明申请
    METHODS OF PREDICTING AND MONITORING TYROSINE KINASE INHIBITOR THERAPY 审中-公开
    预测和监测酪氨酸激酶抑制剂治疗方法

    公开(公告)号：US20110244465A1

    公开(公告)日：2011-10-06

    申请号：US13024139

    申请日：2011-02-09

    申请人： Jeanne Harvey ,  Bruce Neri ,  Sharat Singh

    发明人： Jeanne Harvey ,  Bruce Neri ,  Sharat Singh

    IPC分类号： C12Q1/02 ,  C12Q1/68

    CPC分类号： G01N33/57484 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/154 ,  G01N2333/91215 ,  G01N2500/04 ,  G01N2800/52 ,  G16B20/00 ,  G16B40/00

    摘要： The present invention provides methods for analyzing a combination of biomarkers to individualize tyrosine kinase inhibitor therapy in patients who have been diagnosed with cancer. In particular, the assay methods of the present invention are useful for predicting, identifying, or monitoring the response of a tumor, tumor cell, or patient to treatment with a tyrosine kinase inhibitor using an algorithm based upon biomarker profiling. The assay methods of the present invention are also useful for predicting whether a patient has a risk of developing toxicity or resistance to treatment with a tyrosine kinase inhibitor. In addition, the assay methods of the present invention are useful for monitoring tyrosine kinase inhibitor therapy in a patient receiving the drug to evaluate whether the patient will develop resistance to the drug. Furthermore, the assay methods of the present invention are useful for optimizing the dose of a tyrosine kinase inhibitor in a patient receiving the drug to achieve therapeutic efficacy and/or reduce toxic side-effects.

    摘要翻译： 本发明提供了用于分析已经被诊断患有癌症的患者中的酪氨酸激酶抑制剂治疗的生物标志物的组合的方法。 特别地，本发明的测定方法可用于使用基于生物标志物分析的算法预测，鉴定或监测肿瘤，肿瘤细胞或患者用酪氨酸激酶抑制剂治疗的应答​​。 本发明的测定方法也可用于预测患者是否具有产生毒性或抗酪氨酸激酶抑制剂治疗的风险。 此外，本发明的测定方法可用于监测接受药物的患者中的酪氨酸激酶抑制剂治疗，以评估患者是否会产生对药物的抗药性。 此外，本发明的测定方法可用于优化接受该药物的患者中的酪氨酸激酶抑制剂的剂量以达到治疗功效和/或减少毒副作用。

    Assay for detecting methylation status by methylation specific primer extension (MSPE)
    8.
    发明申请
    Assay for detecting methylation status by methylation specific primer extension (MSPE) 审中-公开
    通过甲基化特异性引物延伸（MSPE）检测甲基化状态的测定

    公开(公告)号：US20050214812A1

    公开(公告)日：2005-09-29

    申请号：US11010980

    申请日：2005-06-07

    申请人： Zheng Li ,  Jeanne Harvey

    发明人： Zheng Li ,  Jeanne Harvey

    IPC分类号： C12N15/09 ,  C12M1/00 ,  C12P19/34 ,  C12Q1/68

    CPC分类号： C12Q1/6827 ,  C12Q2523/125 ,  C12Q2535/125

    摘要： The present invention relates to detecting the relative methylation levels at one or more CpG sites on a nucleic acid molecule, by using the methylation specific primer extension reaction (MSPE). MSPE uses an agent to modify unmethylated cytosine at a CpG site to uracil and subsequently amplify the chemically treated nucleic acids. The MSPE primers distinguishing between unmethylated and methylated CpG sites are provided to conduct MSPE. Relative methylation levels at one or more CpG sites are performed by detecting the signal intensity of labels incorporated into the MSPE reaction products.

    摘要翻译： 本发明涉及通过使用甲基化特异性引物延伸反应（MSPE）来检测核酸分子上一个或多个CpG位点处的相对甲基化水平。 MSPE使用试剂将CpG位点处的未甲基化胞嘧啶修饰为尿嘧啶，随后扩增经化学处理的核酸。 提供区分非甲基化和甲基化CpG位点的MSPE引物进行MSPE。 通过检测结合到MSPE反应产物中的标记的信号强度来进行一个或多个CpG位点的相对甲基化水平。